

10/599,824

DOCKET NO.: 133087.14701 (101431-1P US)

PATENT

In the Specification:

BSN 1-26-08

Please amend the table beginning at page 12, line ¹⁰~~13~~ of the International PCT publication as follows:

--Examples ~~2-29~~ 2-28:

The compounds shown in the following table were prepared in a manner analogous to that described in Example 1:

Ex. No.		Name	MW	MS m/z (M+H)+
2 <u>1</u>		4-({[2-(3,4-dichlorophenyl)-2-piperazin-1-ylethoxy]methyl}-3-methoxy-2-naphthonitrile <u>4-({[2-(3-Chloro-4-fluorophenyl)-2-piperazin-1-ylethoxy]methyl}-3-methoxy-2-naphthonitrile</u>	470.40	470.2, 472.2 <u>454.4</u>
3 <u>2</u>		3-methoxy-4-({[2-piperazin-1-yl]-2-[3-(trifluoromethoxy)-phenyl]ethoxy}methyl)-2-naphthonitrile <u>4-({[2-(3,4-dichlorophenyl)-2-piperazin-1-ylethoxy]methyl}-3-methoxy-2-naphthonitrile</u>	485.51 <u>470.40</u>	486.4 <u>470.2, 472.2</u>
4 <u>3</u>		3-methoxy-4-({[2-piperazin-1-yl]-2-[3-(trifluoromethyl)-phenyl]ethoxy}methyl)-2-naphthonitrile <u>3-methoxy-4-({[2-piperazin-1-yl]-2-[3-(trifluoromethoxy)-phenyl]ethoxy}methyl)-2-naphthonitrile</u>	469.51 <u>485.51</u>	470.5 <u>486.4</u>